Form 4: Atossa Therapeutics Director Remmel H. Lawrence Acquires 10,000 Shares

Director Remmel H. Lawrence of Atossa Therapeutics, Inc. purchased 10,000 shares of common stock at $0.7 per share on March 26, 2025.

Summary

• On March 26, 2025, Remmel H. Lawrence, a director of Atossa Therapeutics, Inc., acquired 10,000 shares of common stock.
• The purchase price was $0.7 per share.
• Following the transaction, Mr. Lawrence directly owns 10,257 shares of Atossa Therapeutics common stock.
• The filing also notes a 12:1 reverse stock split that occurred in April 2018.

Sentiment

Score: 6

Explanation: A director purchasing shares is generally a positive sign, but the limited information and small transaction size temper the overall sentiment.

Positives

• A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders (officers, directors, or those holding 10% or more of a company's shares) buy or sell stock in their own companies. These filings are closely watched by investors as they can provide insights into management's view of the company's prospects.

Stakeholder Impact

• The purchase could have a slightly positive impact on shareholder sentiment.

Key Dates

Keywords

Atossa Therapeutics, Remmel H. Lawrence, stock purchase, director, Form 4, beneficial ownership, ATOS